Analytics

Feliza Mirasol is the science editor for 

Videos

Jay Rajagopalan, senior director—Engineering & Product Management for Malema at PSG Biotech, shared insights at on how current industry trends are shaping the development and advancement of sensor technologies.

A Look at the Impact of Industry Trends on Sensor Technologies (INTERPHEX 2024)

Articles

Ricoh aims to create novel disease models for R&D using ERS Genomics’ CRISPR/Cas9 genome editing technology.

Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology

Ben Moree is principal scientist at Quantum-Si.

There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.

Drug Digest: The Rush for Quality Data and the Means to Protect It

The addition of another amino acid recognizer as well as improvements in surface chemistry, reagents, and software expand the proteome coverage of Quantum-Si’s Platinum sequencing platform.

Quantum-Si Launches Platform Enhancements for Protein Sequencer

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Effective analytics will eliminate failures, deviations, and non-conformances.

Analyzing Exabytes

Strategizing a PK/PD study approach in early phase development facilitates a successful clinical progression.

Addressing PK/PD Study Design Early in Development

Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.

Lonza and Oxford Nanopore Partner on mRNA Analytics

Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument. 

Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

Laboratory Equipment and Instruments